Lactobacillus species are potential probiotic bacteria for humans because of their capacity to improve certain biological functions in the host's immune system. In this study, we focused on three peptidoglycans (PGNs) derived from different Lactobacillus strains and investigated each PGN's anti-inflammatory capacity. Each PGN was analyzed using HPLC, MALDI-TOF/TOF MS and FTIR. All three PGNs displayed a β-1,4-linked N-acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc) structure with some modifications in the polypeptides at the end of the MurNAc residue. In a new insight, we found that PGNs inhibit the release of inflammatory cytokines in LPS-induced RAW 264.7 cells; a capacity that may be related to the TLR-4 pathway. The goal for exploring PGN diversity in Lactobacillus strains is to better understand the potential use of Lactobacillus PGNs in food and pharmaceutical applications.
Keywords: Anti-inflammatory capacity; DHB (PubChem CID: 24101); FITC (PubChem CID: 18730); HT-29 cells; Lactobacillus strains; N-acetylglucosamine (PubChem CID: 11861101); N-acetylmuramic acid (PubChem CID: 12917652); PGN diversity; Peptidoglycan (PubChem CID: 9816401); RAW 264.7 cells.
Copyright © 2015 Elsevier Ltd. All rights reserved.